Evidence map›Paper›PMID 42054250›Full record

ArticleJournal of medicinal chemistry2026

Covalent Targeting of Histidine Residues: A Ligand-First Approach.

Giulia Alboreggia, Emma L Atienza, Kendall Muzzarelli, Zahra Assar, Maurizio Pellecchia

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Giulia AlboreggiaDivision of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Avenue, Riverside, California 92521, United States.
Emma L AtienzaDivision of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Avenue, Riverside, California 92521, United States.
Kendall MuzzarelliCayman Chemical Co, 1180 E. Ellsworth road, Ann Arbor, Michigan 48108, United States.
Zahra AssarCayman Chemical Co, 1180 E. Ellsworth road, Ann Arbor, Michigan 48108, United States.
Maurizio PellecchiaDivision of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Avenue, Riverside, California 92521, United States.ORCID 0000-0001-5179-470X

Funding

Project 2U54CA285116 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI ERNEST MARTINEZ, Victoria L. Seewaldt · 2023 to 2026
$6.8M
Research EducationU54CA285114 · NCI · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI ERNEST MARTINEZ, Victoria L. Seewaldt · 2023 to 2026
$6.2M
NCI NIH HHS U54 CA285114NCI NIH HHS U54 CA285116
6 · The paper itself

Abstract

The design of irreversible drugs has resulted, over the past decade, in several new therapeutics in oncology that present improved pharmacodynamic and pharmaco

Indexed as

HistidineAcetamidesBinding SitesLigandsModels, MolecularStructure-Activity RelationshipAcetamideschloroacetamideHistidineLigands

Identifiers

PMID42054250
PMCPMC13182766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.